BioPharma Dive November 30, 2022
The priority review voucher is one of two Bluebird received for winning FDA approvals of its rare disease gene therapies Zynteglo and Skysona.
Gene therapy developer Bluebird bio has sold a voucher that speeds up U.S. drug reviews to Dutch biotechnology company Argenx for $102 million, giving it a much needed cash infusion that will more than double its expected year-end holdings.
The sale, announced by Bluebird Wednesday, comes after the Food and Drug Administration approved two of the company’s rare disease gene therapies, Zynteglo and Skysona, both of which came with so-called priority review vouchers that can be resold to other companies for use on their new drug applications.
The vouchers have recently commanded prices between $100 million and...
Today's Sponsors
Today's Sponsor